MedKoo Cat#: 406820 | Name: PKI 14-22 amide, myristoylated

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PKI 14-22 amide, myristoylated, also known as myristoylated protein kinase A inhibitor amide 14-22, is a PKA inhibitor. PKI 14-22 amide, myristoylated is a cell-permeable version of protein kinase inhibitor PKI (14-22) amide. The non-myristoylated version inhibits protein kinase A (Ki = 36 nM), inhibits cell growth and induces apoptosis in human pancreatic cancer cells (PANC-1).

Chemical Structure

PKI 14-22 amide, myristoylated
PKI 14-22 amide, myristoylated
CAS#201422-03-9

Theoretical Analysis

MedKoo Cat#: 406820

Name: PKI 14-22 amide, myristoylated

CAS#: 201422-03-9

Chemical Formula: C53H100N20O12

Exact Mass: 1208.7830

Molecular Weight: 1209.51

Elemental Analysis: C, 52.63; H, 8.33; N, 23.16; O, 15.87

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
PKI 14-22 amide, myristoylated; PKI 14-22 amide, myristoylated; Myr-Gly-Arg-Thr-Gly-Arg-Arg-Asn-Ala-Ile-NH2. Sequence: GRTGRRNAI.
IUPAC/Chemical Name
(S)-N1-((S)-1-(((2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)-2-((2S,5S,11S,14S)-2,5,14-tris(3-((diaminomethylene)amino)propyl)-11-((R)-1-hydroxyethyl)-4,7,10,13,16,19-hexaoxo-3,6,9,12,15,18-hexaazadotriacontanamido)succinamide
InChi Key
GQPQKQWUUHDDIS-JDLJUXOTSA-N
InChi Code
InChI=1S/C53H100N20O12/c1-6-8-9-10-11-12-13-14-15-16-17-24-39(76)65-29-40(77)69-35(22-19-26-63-52(58)59)48(83)73-43(33(5)74)50(85)66-30-41(78)68-34(21-18-25-62-51(56)57)46(81)70-36(23-20-27-64-53(60)61)47(82)71-37(28-38(54)75)49(84)67-32(4)45(80)72-42(44(55)79)31(3)7-2/h31-37,42-43,74H,6-30H2,1-5H3,(H2,54,75)(H2,55,79)(H,65,76)(H,66,85)(H,67,84)(H,68,78)(H,69,77)(H,70,81)(H,71,82)(H,72,80)(H,73,83)(H4,56,57,62)(H4,58,59,63)(H4,60,61,64)/t31-,32-,33+,34-,35-,36-,37-,42-,43-/m0/s1
SMILES Code
CCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,209.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nalli AD, Kumar DP, Mahavadi S, Al-Shboul O, Alkahtani R, Kuemmerle JF, Grider JR, Murthy KS. Hypercontractility of intestinal longitudinal smooth muscle induced by cytokines is mediated by the nuclear factor-κB/AMP-activated kinase/myosin light chain kinase pathway. J Pharmacol Exp Ther. 2014 Jul;350(1):89-98. doi: 10.1124/jpet.113.212522. Epub 2014 Apr 25. PubMed PMID: 24769544; PubMed Central PMCID: PMC4056271. 2: Li W, Cui M, Wei Y, Kong X, Tang L, Xu D. Inhibition of the expression of TGF-β1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cell Physiol Biochem. 2012;30(3):749-57. doi: 10.1159/000341454. Epub 2012 Aug 2. PubMed PMID: 22890152. 3: Choi S, Kim MY, Joo KY, Park S, Kim JA, Jung JC, Oh S, Suh SH. Modafinil inhibits K(Ca)3.1 currents and muscle contraction via a cAMP-dependent mechanism. Pharmacol Res. 2012 Jul;66(1):51-9. doi: 10.1016/j.phrs.2012.02.009. Epub 2012 Mar 5. PubMed PMID: 22414869. 4: Collett GP, Goh XF, Linton EA, Redman CW, Sargent IL. RhoE is regulated by cyclic AMP and promotes fusion of human BeWo choriocarcinoma cells. PLoS One. 2012;7(1):e30453. doi: 10.1371/journal.pone.0030453. Epub 2012 Jan 17. PubMed PMID: 22272352; PubMed Central PMCID: PMC3260294. 5: Kockx M, Guo DL, Huby T, Lesnik P, Kay J, Sabaretnam T, Jary E, Hill M, Gaus K, Chapman J, Stow JL, Jessup W, Kritharides L. Secretion of apolipoprotein E from macrophages occurs via a protein kinase A and calcium-dependent pathway along the microtubule network. Circ Res. 2007 Sep 14;101(6):607-16. Epub 2007 Jul 27. PubMed PMID: 17660382. 6: Liu H, Farley JM Sr. Prostaglandin E2 enhances acetylcholine-induced, Ca2+-dependent ionic currents in swine tracheal mucous gland cells. J Pharmacol Exp Ther. 2007 Aug;322(2):501-13. Epub 2007 May 4. PubMed PMID: 17483294. 7: Xiao B, Zhong G, Obayashi M, Yang D, Chen K, Walsh MP, Shimoni Y, Cheng H, Ter Keurs H, Chen SR. Ser-2030, but not Ser-2808, is the major phosphorylation site in cardiac ryanodine receptors responding to protein kinase A activation upon beta-adrenergic stimulation in normal and failing hearts. Biochem J. 2006 May 15;396(1):7-16. PubMed PMID: 16483256; PubMed Central PMCID: PMC1449991. 8: Kline LW, Karpinski E. Progesterone inhibits gallbladder motility through multiple signaling pathways. Steroids. 2005 Aug;70(9):673-9. PubMed PMID: 15916787. 9: Chin EC, Abayasekara DR. Progesterone secretion by luteinizing human granulosa cells: a possible cAMP-dependent but PKA-independent mechanism involved in its regulation. J Endocrinol. 2004 Oct;183(1):51-60. PubMed PMID: 15525573. 10: Koga T, Takahashi M. Quantal size of catecholamine release from rat chromaffin cells is regulated by tonic activity of protein kinase A. Neurosci Lett. 2004 Apr 29;360(3):145-8. PubMed PMID: 15082154. 11: Farrow B, Rychahou P, Murillo C, O'connor KL, Iwamura T, Evers BM. Inhibition of pancreatic cancer cell growth and induction of apoptosis with novel therapies directed against protein kinase A. Surgery. 2003 Aug;134(2):197-205. PubMed PMID: 12947318. 12: Miyashita K, Itoh H, Sawada N, Fukunaga Y, Sone M, Yamahara K, Yurugi T, Nakao K. Adrenomedullin promotes proliferation and migration of cultured endothelial cells. Hypertens Res. 2003 Feb;26 Suppl:S93-8. PubMed PMID: 12630817. 13: Park SH, Shin SS, Han HJ. High glucose levels alter angiotensin II-induced Ca(2+) uptake via PKC and cAMP pathways in renal proximal tubular cells. Kidney Blood Press Res. 2001;24(2):84-91. PubMed PMID: 11435739. 14: Park S, Taub M, Han H. Regulation of phosphate uptake in primary cultured rabbit renal proximal tubule cells by glucocorticoids: evidence for nongenomic as well as genomic mechanisms. Endocrinology. 2001 Feb;142(2):710-20. PubMed PMID: 11159843. 15: Han HJ, Lee YH, Park SH. Estradiol-17beta-BSA stimulates Ca(2+) uptake through nongenomic pathways in primary rabbit kidney proximal tubule cells: involvement of cAMP and PKC. J Cell Physiol. 2000 Apr;183(1):37-44. PubMed PMID: 10699964. 16: Xan HJ, Kim DH, Park SH. Regulatory mechanisms of Na/Pi cotransporter by glucocorticoid in renal proximal tubule cells: involvement of cAMP and PKC. Kidney Blood Press Res. 2000;23(1):1-9. PubMed PMID: 10567847. 17: Han HJ, Park SH, Lee JC, Lee HB, Park HS. Leukotriene D4 inhibits Na+ uptake through cAMP and PLC pathways in primary cultured renal proximal tubular cells. Kidney Blood Press Res. 1999;22(3):106-13. PubMed PMID: 10394108.